Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 6;16(6):847.
doi: 10.3390/ph16060847.

Sucrosomial® Iron: An Updated Review of Its Clinical Efficacy for the Treatment of Iron Deficiency

Susana Gómez-Ramírez  1 , Elisa Brilli  2 , Germano Tarantino  3 , Domenico Girelli  4 , Manuel Muñoz  5
Affiliations
Review

Sucrosomial® Iron: An Updated Review of Its Clinical Efficacy for the Treatment of Iron Deficiency

Susana Gómez-Ramírez et al. Pharmaceuticals (Basel). .

Abstract

Iron deficiency (ID) and iron deficiency anemia (IDA) are highly prevalent worldwide. Oral iron salts, especially ferrous sulfate, are commonly used for the treatment of iron deficiency (ID). However, its use is associated with gastrointestinal side effects, thus compromising treatment compliance. Intravenous iron administration is a more costly and logistically complex alternative and is not risk-free, as infusion and hypersensitivity reactions may occur. Sucrosomial® iron is an oral formulation consisting of ferric pyrophosphate conveyed by a phospholipid and sucrester matrix (sucrosome®). Intestinal Sucrosomial® iron absorption is mediated by enterocytes and M cells, through the paracellular and transcellular routes, and occurs mostly as intact particles. These pharmacokinetic properties of Sucrosomial® iron result in higher iron intestinal absorption and excellent gastrointestinal tolerance compared to oral iron salts. The evidence derived from clinical studies supports the use of Sucrosomial® iron as a valid first option for the treatment of ID and IDA, especially for subjects who are intolerant or refractory to conventional iron salts. Newer evidence also demonstrates the effectiveness of Sucrosomial® iron, with a lower cost and fewer side effects, in certain conditions usually treated with IV iron in current clinical practice.

Keywords: Sucrosomial® iron; anemia; bioavailability; efficacy; intravenous iron; iron deficiency; oral iron salts; patient blood management; tolerability.

PubMed Disclaimer

Conflict of interest statement

S.G.-R. has nothing to declare; E.B. is an Alesco S.r.l. employee; G.T. is a Pharmanutra S.p.A. employee; D.G. has received fees as a consultant (Advisory Board) from Sanofi, Novo Nordisk, Vifor Pharma, and Kedrion; M.M. has received industry-supplied honoraria for consultancy, lectures, and/or travel support from Pharmacosmos, Vifor Pharma, Zambon, and Pharmanutra and is a member of the editorial board of the journals Revista Española de Anestesiología y Reanimación, Medicina Intensiva, and Blood Transfusion.

Figures

Figure 1
Figure 1
Estimated prevalence of iron deficiency in different clinical settings (taken from Ref. [18], with permission).
Figure 2
Figure 2
Schematic structure of Sucrosomial® iron.
See this image and copyright information in PMC

References

    1. Gardner W., Kassebaum N. Global, Regional, and National Prevalence of Anemia and Its Causes in 204 Countries and Territories, 1990–2019. Curr. Dev. Nutr. 2020;4((Suppl. S2)):830. doi: 10.1093/cdn/nzaa053_035. - DOI
    1. Safiri S., Kolahi A.-A., Noori M., Nejadghaderi S.A., Karamzad N., Bragazzi N.L., Sullman M.J.M., Abdollahi M., Collins G.S., Kaufman J.S., et al. Burden of anemia and its underlying causes in 204 countries and territories, 1990–2019: Results from the Global Burden of Disease Study 2019. J. Hematol. Oncol. 2021;14:185. doi: 10.1186/s13045-021-01202-2. - DOI - PMC - PubMed
    1. Pasricha S.-R., Tye-Din J., Muckenthaler M.U., Swinkels D.W. Iron deficiency. Lancet. 2021;397:233–248. doi: 10.1016/S0140-6736(20)32594-0. - DOI - PubMed
    1. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211–1259. doi: 10.1016/S0140-6736(17)32154-2. - DOI - PMC - PubMed
    1. Muñoz M., Peña-Rosas J.P., Robinson S., Milman N., Holzgreve W., Breymann C., Goffinet F., Nizard J., Christory F., Samama C.-M., et al. Patient blood management in obstetrics: Management of anaemia and haematinic deficiencies in pregnancy and in the post-partum period: NATA consensus statement. Transfus. Med. 2018;28:22–39. doi: 10.1111/tme.12443. - DOI - PubMed

LinkOut - more resources